Immunocore (NasdaqGS:IMCR) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Company ParticipantsBahija Jallal - CEOGraig Suvannavejh - Managing DirectorMohammed Dar - EVP of Clinical Development and Chief Medical OfficerMorgan Morse - Investor Relations ManagerPaul Jeng - VP of Biotechnology Equity ResearchRajan Sharma - Pharma and Biotech Equity ResearchRalph Torbay - EVP of CommercialSean Laaman - Executive DirectorTravis Coy - CFO and Head of Corporate DevelopmentConference Call ParticipantsEric Schmi ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and improve content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the broadening of its NAD+ precursor intellectual property (IP) portfolio with the newly granted U.S. Patent No. 12,558,367, which covers the methods of use of nicotinamide riboside (NR) and derivatives in intravenous and injectable formulations. Rob Fried, CEO of Niagen Bioscience, commented, " ...

K2Global SMB500 Platform deploys blockchain-enabled industrial ecosystems in Atlanta, GA and Dallas, TX — strengthening American supply chains and manufacturing capacityATLANTA and DALLAS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- JP3E Holdings Inc. (OTC: JPTE) today announced a strategic partnership with TBURN Chain Foundation to deploy the K2Global SMB500 Platform through Innovation City Kwave hubs in Atlanta, Georgia and Dallas, Texas. The K2Global SMB500 initiative integrates 500 elite Korean small and mid-size ...

PHILADELPHIA, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today announced that the company will participate in the following upcoming investor conferences in March: TD Cowen 46th Annual Health Care Conference: Fireside chat at 9:50 a.m. ET on Wednesday, March 4, 2026, in Boston, MA. Leerink Partners Global H ...

Taipei, Taiwan, Feb. 25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that its subsidiary YD Bio USA, Inc. (“YD Bio USA”) entered into a Master Strategic Alliance Agreement (the “Agreement”) with YC Biotech Co., Ltd. (“YC Biotech”) on February 24, 2026. This partnership represents a pivotal advancement in the Company’s mission, establi ...

WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be participating in the following upcoming investor conferences in March: TD Cowen 46th Annual Health Care Conference, Boston, MAWednesday, March 4, 2026, Fireside Chat - 9:50 a.m. ET2026 Leerink Partners Global ...

分组1 - Axogen, Inc. (AXGN) reported a 4Q25 non-GAAP EPS of $0.07, missing expectations by approximately $0.03 [1] - Revenue for the quarter was $59.9 million, aligning with estimates and reflecting a year-over-year growth of 21.3% [1]

AbCellera Biologics Inc. (NASDAQ:ABCL) shares are trending on Wednesday.Earnings Beat Drives After-Hours RallyShares of the Vancouver-based biotechnology company rose 9.32% in after-hours trading on Tuesday to $3.52 after the company reported its fourth-quarter 2025 earnings.AbCellera Biologics posted earnings per share of negative $0.03, compared with an estimate of negative $0.18, representing an 83.33% earnings outperformance.Its revenue also increased by $39.80 million from a year earlier.The fourth-qua ...

Beijing will likely stick with a ~5% GDP growth target for 2026, but policy remains cushioning over lifting. We expect a flat initial fiscal envelope, a continued focus on tech and public capex, and reactive guardrails for consumption and property – keeping reflation a slow burn. February 24, 2026 12:16 PM GMT China Musings | Asia Pacific NPC Preview: Policy Continuity, Not a Pivot Key Takeaways A 5% national GDP growth target to stay: Two thirds of provinces have trimmed 2026 growth targets, triggering spe ...